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Digital pathology is increasingly prominent in neurodegenerative disease research, but
variability in immunohistochemical staining intensity between staining batches prevents
large-scale comparative studies. Here we provide a statistically rigorous method to
account for staining batch effects in a large sample of brain tissue with frontotemporal
lobar degeneration with tau inclusions (FTLD-Tau, N = 39) or TDP-43 inclusions (FTLD-
TDP, N = 53). We analyzed the relationship between duplicate measurements of
digital pathology, i.e., percent area occupied by pathology (%AO) for grey matter (GM)
and white matter (WM), from two distinct staining batches. We found a significant
difference in duplicate measurements from distinct staining batches in FTLD-Tau (mean
difference: GM = 1.13 ± 0.44, WM = 1.28 ± 0.56; p < 0.001) and FTLD-TDP
(GM = 0.95 ± 0.66, WM = 0.90 ± 0.77; p < 0.001), and these measurements
were linearly related (R-squared [Rsq]: FTLD-Tau GM = 0.92, WM = 0.92; FTLD-TDP
GM = 0.75, WM = 0.78; p < 0.001 all). We therefore used linear regression to transform
%AO from distinct staining batches into equivalent values. Using a train-test set design,
we examined transformation prerequisites (i.e., Rsq) from linear-modeling in training
sets, and we applied equivalence factors (i.e., beta, intercept) to independent testing
sets to determine transformation outcomes (i.e., intraclass correlation coefficient [ICC]).
First, random iterations (×100) of linear regression showed that smaller training sets
(N = 12–24), feasible for prospective use, have acceptable transformation prerequisites
(mean Rsq: FTLD-Tau ≥0.9; FTLD-TDP ≥0.7). When cross-validated on independent
complementary testing sets, in FTLD-Tau, N = 12 training sets resulted in 100% of GM
and WM transformations with optimal transformation outcomes (ICC ≥ 0.8), while in
FTLD-TDP N = 24 training sets resulted in optimal ICC in testing sets (GM = 72%,
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WM = 98%). We therefore propose training sets of N = 12 in FTLD-Tau and N = 24
in FTLD-TDP for prospective transformations. Finally, the transformation enabled us
to significantly reduce batch-related difference in duplicate measurements in FTLD-Tau
(GM/WM: p < 0.001 both) and FTLD-TDP (GM/WM: p < 0.001 both), and to decrease
the necessary sample size estimated in a power analysis in FTLD-Tau (GM:−40%; WM:
−34%) and FTLD-TDP (GM: −20%; WM: −30%). Finally, we tested generalizability of
our approach using a second, open-source, image analysis platform and found similar
results. We concluded that a small sample of tissue stained in duplicate can be used
to account for pre-analytical variability such as staining batch effects, thereby improving
methods for future studies.
Keywords: digital histopathology, frontotemporal lobar degeneration, pre-analytical variability, batch effects,
linear transformation method, validation of a method
INTRODUCTION
Digital pathology is emerging as an important discipline in
clinical pathology, biomedical research and medical education
(Huisman, 2012; Hamilton et al., 2014; Griffin and Treanor,
2017). Digital methods of pathological analysis are also
increasingly used in neurodegenerative disease research as
they provide a high-throughput, objective measure of disease
severity as compared with traditional ordinal ratings. Indeed,
this quantitative approach to measuring pathological burden
provides increased sensitivity to detect clinicopathological
correlations (Neltner et al., 2012; Walker et al., 2015, 2017; Irwin
et al., 2016b; Ferman et al., 2018), which are critical to improve
the antemortem diagnosis of neurodegenerative diseases.
This is especially important in less common, heterogeneous
disorders such as frontotemporal lobar degeneration (FTLD)
(Irwin et al., 2015).
Frontotemporal lobar degeneration comprises a
heterogeneous group of neuropathologies, which present
clinically as frontotemporal dementia syndromes (Irwin et al.,
2015). The two most common FTLD neuropathologies are
frontotemporal lobar degeneration with inclusions of the protein
tau (FTLD-Tau) and frontotemporal lobar degeneration with
inclusions of the transactive response DNA-binding protein of
43 kDa (FTLD-TDP) (Mackenzie et al., 2010; Irwin et al., 2015).
FTLD-Tau can be classified into different neuropathological
sub-entities with distinct morphological features, such as Pick’s
disease (PiD), corticobasal degeneration (CBD), and progressive
supranuclear palsy (PSP) (Dickson et al., 2011; Kovacs, 2015).
Genetically, mutations in the MAPT gene have been associated
with FTLD-Tau (Sieben et al., 2012). FTLD-TDP is subdivided
into type A-E based on the predominant type of inclusions
(Mackenzie et al., 2011; Lee et al., 2017), and these have been
variably associated with genetic mutations in a few different genes
(e.g., C9orf72, GRN, TARDBP, VCP) (Sieben et al., 2012). Distinct
FTLD proteinopathies cannot be differentiated during life, which
poses a significant challenge for disease modifying therapies in
development targeting tau and TDP-43 pathways of degeneration
(Boxer et al., 2013). Thus, postmortem comparative studies of
clinically similar FTLD-Tau and FTLD-TDP are urgently needed
to improve antemortem diagnosis (Irwin et al., 2015).
With the increasing use of digital pathology, it is critical
to develop rigorous empirically defined methods to account
for the multiple pre-analytical factors that could influence
these digital measurements. One major obstacle to large-scale
comparative autopsy studies is the inability to simultaneously
stain large amounts of tissue in a single staining batch.
Yet, the use of multiple staining batches may be affected
by staining batch effects, i.e., a potential important source
of pre-analytical variability related to immunohistochemical
(IHC) staining intensity that prevents valid inter-comparability
of digital pathology measurements. It may be possible to
account for this batch-related variability statistically, enabling
to merge data from distinct staining batches without major
issues of comparability, but we are not aware of any published
methodologies used in neurodegenerative disease research.
It is advantageous for research centers to generate cumulative
digital pathology data from prospective autopsies, and to build a
library of digital pathology data by adding newly generated digital
measurements to archived legacy data from prior autopsies.
This strategy would preserve resources, and facilitate large-
scale clinical, genetic and neuroimaging correlation studies
urgently needed to improve the antemortem diagnosis of
neurodegenerative diseases. While there is limited empirical
evidence to guide methods for merging data obtained from tissue
stained in different staining batches, this would be necessary to
ameliorate comparability of digital measurements, and to prevent
duplication of efforts of having to re-stain large amounts of tissue
for prospective large-scale projects. Here we empirically test
methodological steps to develop a working standard operating
procedure (SOP) to transform digital pathology data from a
new staining batch (i.e., staining batch 2 [SB2]) into equivalent
values to a previous staining batch (i.e., staining batch 1 [SB1]),
using a set of tissue samples stained in duplicate (i.e., in both
SB1 and SB2). We test this approach in a large sample of
FTLD with either tau inclusions (FTLD-Tau) or transactive
response DNA binding protein 43 kDa (TDP-43) inclusions
(FTLD-TDP). We focus on FTLD pathologies, since these are
two distinct monoproteinopathies with varied histopathological
morphologies in both grey matter (GM) and white matter (WM)
(Irwin et al., 2015), and are thus ideal to test for variation due
to staining batch effects as opposed to AD or LBD, which often
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have mixed pathology (Montine et al., 2012; McKeith et al., 2017).
These data provide an important methodological approach to
guide future digital pathology analysis in brain bank programs
for a spectrum of age-related neurodegenerative disorders.
MATERIALS AND METHODS
Patients
We selected a convenience sample of brain tissue from FTLD
patients with high availability to use for comparative analysis
of tissue samples stained in duplicate. Patients were evaluated
clinically at the Penn Frontotemporal Degeneration Center
or Alzheimer’s Disease Center and met clinical criteria for
an FTD spectrum diagnosis (Mesulam, 2001; Rascovsky
et al., 2011). Patients were autopsied at the Penn Center
for Neurodegenerative Disease Research with a primary
neuropathological diagnosis of FTLD (n = 68) with either
FTLD-Tau (n = 26) or FTLD-TDP (n = 42) (Mackenzie et al.,
2010; Montine et al., 2012). We did not include less common
neuropathologies associated with clinical FTD, including AD,
or FUS proteinopathy (Irwin et al., 2015). This study was
carried out in accordance with the recommendations of the
Penn Institutional Review Board (IRB) on human subjects
research protections guidelines. The protocol was approved by
the Penn IRB. All subjects gave written informed consent prior
to participation, in accordance with the Declaration of Helsinki.
Tissue Processing and
Neuropathological Diagnosis
All tissue was processed in an identical manner as described
(Toledo et al., 2014; Irwin et al., 2016b). Briefly, fresh tissue
samples were fixed overnight in 10% neutral-buffered formalin,
or 70% ethanol with 150 mM sodium chloride in a minority
of cases (N = 4 in FTLD-Tau, N = 4 in FTLD-TDP), which
has been previously validated using our digital method (Irwin
et al., 2016b). Tissue samples were trimmed, placed into cassettes
and processed through a series of alcohol, xylene and Surgipath
EM-400 paraffin embedding media (Leica Microsystems; Buffalo
Grove, IL, United States) with incubations overnight (70%
ethanol × 2 h, 80% ethanol × 1 h, 95% ethanol × 1 h, 95%
ethanol × 2 h, 100% ethanol × 2 h, twice, xylene × 30 min,
xylene × 1 h, xylene × 1.5 h, and paraffin × 1 h, three
times) in a Shandon tissue processor (Thermo Fisher Scientific;
Waltham, MA, United States). All incubations were done under
vacuum and at ambient temperature except paraffin (62◦C).
Tissue was embedded into paraffin blocks and 6-µm-thick
sections were cut for analysis. For neuropathological diagnosis,
tissue sections from standard brain regions were immunostained
for tau, amyloid-beta, alpha-synuclein and TDP-43 using well-
characterized antibodies and stained for neuritic plaques using
thioflavin-S as described (Toledo et al., 2014). Neuropathological
diagnoses were established by expert neuropathologists (EBL,
JQT) using standard neuropathological criteria (Mackenzie et al.,
2010; Montine et al., 2012; Lee et al., 2017).
For the current study, IHC was performed using well-
characterized antibodies for phospho-tau (AT8; Millipore)
(Mercken et al., 1992) in FTLD-Tau and TDP-43 (rat monoclonal
TAR5P-1D3, p409/410; Ascenion) (Neumann et al., 2009) in
FTLD-TDP. Each staining batch underwent identical processing
using the same antigen retrieval methods and dilutions optimized
in our lab, i.e., AT8 1:1K dilution with no antigen retrieval
step; p409/410 1:500 dilution with Citrate Antigen Unmasking
Solution (Vector Laboratories, Burgame, CA, United States,
Catalog No: H-3300) as in previous work (Irwin et al., 2016b,
2018; Giannini et al., 2019). The same secondary antibodies were
used in both staining batches of each pathology, i.e., Abcam
(Cambridge, MA, United States, Goat Anti-Rat) for TDP-43 (Cat.
No. ab97054) and Abcam Goat Anti-Mouse (for AT8) (Cat. No.
ab97020). As a chromogen we used ImmPACT DAB kit (Vector
Laboratories, Burgame, CA, United States, Cat. No. SK-4105)
with VECTASTAIN ABC Kit (Vector Laboratories, Burgame,
CA, United States, Cat. No. PK-4000) with identical incubation
and developer times. Digital image acquisition of histology
slides was performed at 20× magnification with transmitted
light microscopy using Lamina (Perkin Elmer, Waltham, MA,
United States) scanner, which has a slide scanning platform
of 6.5 µm2 (i.e., pixel resolution of 0.325 µm), and camera
resolution of 2560 × 2160 with a bit depth of 16. Digital image
acquisition was performed using an autocorrection step for even
illumination, i.e., the scanner captures 10 empty fields of view to
create a compensation image used to obtain evenly illuminated
composite images. Digital images were analyzed using Halo
digital image software v1.90 (Indica Labs, Albuquerque, NM,
United States) as described (Irwin et al., 2016b, 2018). The
digital measurement performed by the Halo software uses a color
deconvolution process as described in our published methods
(Irwin et al., 2016b). Briefly, we used the Area Quantification
v1.0 Tool in Halo to calculate the % of positive pixels from
the chromogen (i.e., %AO). This tool uses color deconvolution
to first separate the chromogen signal from the haematoxylin
counterstain, and then it applies a minimum optical density (OD)
value threshold to exclude background and count the number
of positive pixels for chromogen-labeled pathology in the total
ROI. Detection algorithms for pathology stain and haematoxylin
counterstain were developed empirically as described (Irwin
et al., 2016b). Please see Supplementary Table 1 for the specific
parameters of our detection algorithms.
Validation Procedures
We included available tissue samples from two standard autopsy-
sampled regions with high availability of tissue, i.e., an anterior
region such as mid-frontal cortex (MFC) and a posterior region
such as angular gyrus (ANG), in which we expected a broad
range of pathological severity in our FTLD cohort. We studied
the relationship between duplicate measurements of digital
pathology in adjacent or near adjacent sections of the same
tissue block, one of which was stained in the original staining
batch (SB1), and the other one in a second staining batch
(SB2). To specifically assess the impact of staining batch effects,
duplicate measurements of digital pathology were obtained in
a nearly identical manner except for being stained in two
distinct staining batches. Tissue sections were obtained from
the same cutting ribbon using adjacent or semi-adjacent tissue
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(within ∼50 µm). By visual inspection we found no evident
differences in the distribution and morphology of pathology
between (semi-)adjacent slides, which were nearly identical.
Using digital image analysis, we measured percent of area
occupied by pathology (%AO) in regions of interest (ROIs) for
both GM and WM on each section. GM ROIs were identified as
the largest intact region of parallel-oriented cortex in a section
of brain tissue using our previously validated sampling method
(Irwin et al., 2016b). WM ROIs were sampled as the largest
possible area of deep WM within a tissue section as described
(Irwin et al., 2016b, 2018). To minimize sources of variation
in our measurement other than staining batch effects, we used
the image registration feature of the Halo software to map the
ROI into equivalent regions of (semi-)adjacent tissue sections for
comparable sampling between SB1 and SB2. When this was not
possible, we pasted identical ROIs in a closely matched region
using cellular landmarks (e.g., contours of gyri, blood vessels) to
guide precision for placement.
Unusable or damaged tissue that precluded sampling in a
comparable manner between adjacent sections was excluded
from the analysis (N = 8 tissue samples in FTLD-Tau, N = 12
tissue samples in FTLD-TDP). Minor artifacts and vessels in
brain tissue were sampled out of the area of analysis of digital
images using the cropping tool in the Halo software. In total,
available data from 92 tissue samples, including 39 samples from
26 patients with FTLD-Tau and 53 samples from 42 patients
with FTLD-TDP, were used for this validation (see Table 1).
Each tissue sample had two GM %AO measurements and
two WM %AO measurements (i.e., duplicate measurements),
corresponding to two nearly identical tissue sections, one stained
in SB1 and the other one in SB2. Analyses were performed
distinctly in FTLD-Tau and FTLD-TDP groups because these
pathologies have distinct biology, morphological features and
algorithms for digital image detection (Irwin et al., 2016b, 2018).
Statistics
All statistical analyses were performed using R Statistical Software
3.4.1. Since %AO measurements were not normally distributed,
we applied natural log (ln) transformation and confirmed
normal distribution graphically. We used ln-transformed data
(i.e., ln %AO) in all our validation analyses. Digital pathology
measurements were validated through comparison to gold-
standard ordinal ratings (Supplementary Figure 1) as previously
done (Irwin et al., 2016b, 2018). In this validation dataset (FTLD-
Tau = 39, FTLD-TDP = 53; Table 1), all tissue samples were
stained in duplicate in SB1 and SB2, which gave us the chance (1)
to determine the impact of staining batch effects in a large sample
of data, and (2) to assess our proposed transformation method
using a planned train-test set design.
First, to determine the impact of staining batch effects,
duplicate measurements of pathology in GM and WM ROIs
from SB1 and SB2 were compared using the Bland-Altman (BA)
statistics to test the mean difference between staining batches.
We tested the null hypothesis that the mean difference between
SB1 and SB2 measurements equaled zero using a one-sided t-test.
Significant results were interpreted as providing evidence for
a difference between these duplicate measurements (Bland and
TABLE 1 | Demographic and pathologic characterization of the cohort.
FTLD-Tau (n = 26) FTLD-TDP (n = 42)
Available tissue
Total tissue samples (N) 39 53
ANG tissue samples (N) 20 38
MFC tissue samples (N) 19 15
Demographics
Age at onset (y), mean ± SD 56.4 ± 12.9 59.5 ± 8.5
Age at death (y), mean ± SD 64.5 ± 13.5 65.7 ± 9.5
Disease duration (y), mean ± SD 8.6 ± 4.1 6.7 ± 4.1
Male sex, n (%) 17/26 (65.4) 21/42 (50.0)
Autopsy
PMI (hr), mean ± SD 12.6 ± 6.8 12.9 ± 6.9
Brain weight (gr), mean ± SD 1089.2 ± 156.4 1106.2 ± 194.4
Primary NPD, n (%)
TDP type A (incl. GRN) – 17/42 (45.2)
TDP type B – 13/42 (33.3)
TDP type C – 7/42 (16.7)
TDP type E – 5/42 (11.9)
CBD 5/26 (19.2) –
PSP 4/26 (15.4) –
PiD 9/26 (34.6) –
Tau unclassifiable (incl. MAPT ) 8/26 (30.8) –
Secondary NPD, n (%)
HiSc 1/26 (3.8) 5/42 (11.9)
LBD 2/26 (7.7) 1/42 (2.4)
AGD 0 2/42 (4.8)
Othera 0 2/42 (4.8)
Braakb, n (%)
0 12/26 (46.2) 15/42 (35.7)
1 8/26 (30.8) 19/42 (45.2)
2 1/26 (3.8) 6/42 (14.3)
3 5/26 (19.2) 2/42 (4.8)
CERAD, n (%)
0 22/26 (84.6) 29/42 (69.0)
A 3/26 (11.5) 6/42 (14.3)
B 0 5/42 (11.9)
C 1/26 (3.8) 2/42 (4.8)
Genetic mutations, n (%)
GRN – 8/42 (19.0)
C9orf72 – 15/42 (35.7)
MAPT 6/26 (23.1) –
AD, Alzheimer’s disease; AGD, argyrophilic grain disease; ANG, angular gyrus;
C9orf72, chromosome 9 open reading frame 72; CBD, corticobasal degeneration;
FTLD-Tau, frontotemporal lobar degeneration with inclusions of the tau protein;
FTLD-TDP, frontotemporal lobar degeneration with inclusions of the transactive
response DNA-binding protein 43 kDa; gr, grams; GRN, progranulin gene; hr,
hours; HiSc, hippocampal sclerosis; LBD, Lewy Body disease; MAPT, microtubule-
associated protein tau gene; MFC, mid-frontal cortex; n, number of individuals; N,
number of tissue samples; NPD, neuropathological diagnosis; PiD, Pick’s disease;
PMI, post-mortem interval; PSP, progressive supranuclear palsy; SD, standard
deviation; TDP type A-E, FTLD-TDP subtypes (Mackenzie et al., 2011; Lee et al.,
2017); y, years. aThe two individuals with other secondary pathologies had
minor amounts of cerebrovascular disease in one case, and tangle-predominant
senile dementia in the other case. bFor determination of Braak stages in FTLD-
Tau patients, hippocampal sections were stained with an amyloid-binding dye,
Thioflavin-S, to distinguish co-morbid age-related AD neurofibrillary tangle (NFT)
pathology from primary FTLD-t autopathy as described (Irwin et al., 2017).
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Altman, 1986). Subsequently, the relationship between duplicate
measurements of pathology was explored using univariate
linear regression. Linear modeling used SB1 measurements
as dependent variable and SB2 measurements as independent
variable. Based on the strong linear relationship in both FTLD-
Tau and FTLD-TDP, we proposed to use the linear equivalence
equation to transform SB2 data into values equivalent to SB1:
transformed SB2 (t-SB2) = beta ∗ SB2+ intercept.
Second, we used a planned train-test set design (see below
for details) to validate our proposed transformation method,
which relies upon the use of a small set of tissue stained in each
prospective staining run to account for batch effects in digital
measurements. We validated this method using a validation
protocol involving different steps (Figure 1) to empirically
determine the optimal conditions for a successful transformation
of SB2 measurements into SB1-equivalent units (i.e., t-SB2).
We first looked at transformation prerequisites (i.e., consistent
and sufficiently high goodness of fit in linear models) in
randomly assembled training sets using a relatively small sample
size (i.e., N = 12–24) feasible for use in prospective staining
runs (i.e., one-half to one full staining-rack in our lab) (Step
1). Thereafter, we applied regression-based equivalence factors
(i.e., beta, intercept) to complementary independent testing
sets. Next, we cross-validated transformation outcomes in these
testing sets (Step 2) to verify the accuracy of transformation
(i.e., whether t-SB2 values approximated SB1 values). We
used Step 1 and Step 2 to determine whether a relatively
small set of control tissue (N = 12–24) could be used in
our SOP for prospective data addition to existing datasets.
Finally, we looked at functional outcomes of this approach to
facilitate and improve future studies, such as the reduction
in batch-related difference in duplicate measurements and the
increase in statistical power using transformed %AO values as
opposed to untransformed values from tissue stained in different
batches (Step 3).
Step 1: Examine Transformation Prerequisites in
Feasible-Sized Training Sets
Our first analysis was to determine feasibility of using a
small set of control tissue stained in each prospective staining
run by testing whether small training sets (i.e., N = 12–
24) could provide adequate transformation prerequisites for
our transformation method. We performed linear regressions
relating SB1 (dependent variable) to SB2 (independent variable)
data in randomly subsampled training sets of N = 12 and
N = 24 sample size. We performed 100 iterations per training-
set sample size, and we obtained mean, standard deviation and
a non-parametric quantile-based 95% confidence interval (CI)
for Rsq, beta and intercept. Mean Rsq was our main outcome
as a measure of the goodness of fit of linear modeling in these
random iterations.
Step 2: Cross-Validate Transformation Outcomes in
Independent Testing Sets
Next, we applied equivalence factors (i.e., beta, intercept) of the
linear equivalence equation from iterated linear models (Step 1)
to independent testing sets for cross-validation. Each N = 12 and
N = 24 training set was retested on the respective complementary
testing set (FTLD-Tau: train = 24/test = 15 or train = 12/test = 27;
FTLD-TDP: train = 24/test = 29 or train = 12/test = 41).
FIGURE 1 | Objectives and methods of this validation study and stepwise validation protocol. Panel outlines the aim and methods of our validation study to account
for staining batch effects in digital pathology, including a stepwise protocol to assess relevant aspects of our proposed methodology. delta abs-diff, change in
absolute difference; est. sample size, estimated required sample size in a power analysis; ICC, intraclass correlation coefficient; N, number of tissue samples; Rsq, R
squared; SB1, staining batch 1 (original); SB2, staining batch 2 (new); t-SB2, transformed staining batch 2 (new).
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Our main transformation outcome was intraclass correlation
coefficient (ICC) to assess equivalence between transformed
SB2 measurements (i.e., t-SB2) and original measurements from
SB1. We defined an optimal transformation as ICC ≥ 0.8 and
determined the frequency of optimal transformations out of 100
iterations per training-set sample size (100× N = 24 training
sets, 100× N = 12 training sets) in GM and WM in both FTLD-
Tau and FTLD-TDP.
Step 3: Determine Functional Improvement After
Transformation
Finally, we were interested in determining whether the
application of our transformation method resulted in
improved functional outcomes for the performance of
digital pathology analysis. To this end, we used a single
random train-test split using a N = 12 training set in
FTLD-Tau, and a N = 24 training set in FTLD-TDP, and
we applied the transformation to independent testing
sets including all remaining data in FTLD-Tau (N = 27)
and FTLD-TDP (N = 29). Here, we assessed the impact
of the transformation by testing whether there was a
reduction in the difference between duplicate measurements
from different staining batches. We estimated the mean
difference between duplicate measurements, and visually
compared Bland-Altman plots of test-retest agreement
before and after the transformation (Bland and Altman,
1986). Additionally, we estimated the change in absolute
difference in measurements (i.e., delta abs-diff) between
after the transformation (i.e., absolute difference between
t-SB2 and SB1) and before the transformation (i.e., absolute
difference between SB2 and SB1). We tested whether delta
abs-diff equaled zero using a one-sample t-test, where a
significant finding (p < 0.05) indicated a significant reduction
in batch-related difference in measurements after applying
the transformation.
Finally, we performed a proof-of-concept power analysis
to see how much increased power could be obtained using
alternatively (1) data merged from a random selection of the
original staining batch and the new staining batch without
transformation (i.e., merged untransformed = SB1 + SB2),
and (2) data merged from a random selection of the original
staining batch and the new staining batch after transformation
(i.e., merged transformed = SB1 + t-SB2). To this end, we
used data from the MFC region to derive linear models
in both FTLD-Tau (N = 19) and FTLD-TDP (N = 15).
Next, we applied the transformation to independent testing
sets with data exclusively from the ANG region (FTLD-
Tau = 20; FTLD-TDP = 38). Merged untransformed (SB1
+ SB2) and merged transformed (SB1 + t-SB2) variables
were obtained in testing sets through random assignment
with a 50:50 ration between SB1 and SB2/t-SB2. For our
proof-of-concept power analysis, we calculated the standard
deviation in these two sets of data (i.e., merged untransformed,
merged transformed) and we used it as an approximation of
the overall variance (ANG vs. any hypothetical region) for
possible regional comparisons. We estimated the sample size
necessary to detect varying differences between mean ANG
and another hypothetical regional mean, i.e., 0.2, 0.5, and 0.8,
corresponding to small, medium and large effect sizes (Cohen,
1988). The power analysis was performed with power of 0.8
and alpha of 0.05.
Analysis of Generalizability: Replication of Validation
Outcomes Using an Open-Source Digital Platform
To test the generalizability of our approach, we replicated
the main analyses of this validation using an open-source
image analysis tool, i.e., QuPath (Bankhead et al., 2017).
In QuPath, we quantified %AO by pathology importing the
same RGB color deconvolution algorithms derived in Halo
for tau and TDP-43 inclusions (Supplementary Table 1) in
matched ROIs using the same cellular landmarks for precise
ROI placement in QuPath as in Halo. First, we compared
%AO measurements between SB1 and SB2 in comparable
ROIs to assess whether similar staining batch effects were
observable in another digital platform. Next, we applied the
transformation method to verify the accuracy of transformation
in data obtained from this open-source platform. Our main
outcome measures were ICC, delta abs-diff and Bland-Altman
statistics after transformation in a single random train-
test split (Step 3).
Finally, we also tested an alternative approach to
transformation of %AO values to correct for staining batch
effects using the “Estimate stain vectors” tool in QuPath
(Macenko et al., 2009), which enables to empirically and
systematically develop a new color deconvolution algorithm
for both haematoxylin counterstain and DAB chromogen in
a subsequent staining batch. This QuPath function detects
RGB color signal and plots individual pixel signal in each
vector of RGB (stain vector plots), where the accuracy of
color deconvolution is defined by the presence of pixels within
the confines of the stain vector plots. To develop optimized
algorithms using this tool, we used the same approach as the
one we used to develop our original algorithms as published
(Irwin et al., 2016b). Briefly, RGB and minimum OD values
are estimated empirically in five random slides. Next, the final
RGB and minimum OD parameters of the optimized algorithms
are calculated as the average from these random slides. In
this supplementary analysis, we derived optimized algorithms
in SB2 to compare optimized SB2 measurements to original
SB1 measurements analyzed in QuPath. We tested agreement
between the original algorithm in SB1 and the optimized SB2
algorithm in the full dataset using Bland-Altman analysis for
test-retest agreement.
RESULTS
Data Comparison Between Staining
Batches
Patient demographics are summarized in Table 1. Consistent
with our previous validation of specific algorithms for
digital histopathological analysis, we found digital %AO
measurements reflected gold-standard ordinal ratings of
pathology (Supplementary Figure 1).
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FIGURE 2 | Representative photomicrographs of staining batch variability in FTLD-Tau and FTLD-TDP. Photomicrographs depict a mid-frontal cortex section of
FTLD-Tau (Corticobasal degeneration; left) and FTLD-TDP (TDP type A; right) with raw and digital %AO detection red overlay of pathology in gray matter (top) and
white matter (bottom) in approximate matched areas in staining batch 1 (SB1) vs. staining batch 2 (SB2). There is slightly darker DAB chromogen signal and thus
greater %AO in SB1 compared to SB2. Scale bar = 100 µm. FTLD-Tau, frontotemporal lobar degeneration with inclusions of the tau protein; FTLD-TDP,
frontotemporal lobar degeneration with inclusions of the transactive response DNA-binding protein 43 kDa; GM, gray matter; SB1, staining batch 1 (original); SB2,
staining run 2 (new); WM, white matter.
In our analysis of the impact of staining batch effects on
digital measurements (see Figure 2 for a visual representation
of %AO by tau or TDP-43), we found that in FTLD-Tau the
mean difference between SB1 and SB2 duplicate measurements
was 1.13± 0.44 in GM and 1.28± 0.56 in WM. In FTLD-TDP, the
mean difference between SB1 and SB2 duplicate measurements
was 0.95 ± 0.66 in GM and 0.90 ± 0.77 in WM. Bland-Altman
statistics showed that the mean difference between duplicate
measurements significantly differed from zero (one-sided t-test,
p < 0.001) in both GM and WM in FTLD-Tau and FTLD-
TDP (Figure 3), suggesting that %AO measurements from
different staining batches were not equivalent. The relationship
between SB1 and SB2 was further explored using univariate
linear regression, where SB1 data was employed as the dependent
variable and SB2 as the independent variable. All models (i.e.,
GM and WM in FTLD-Tau and FTLD-TDP) were highly
significant, indicating a linear relationship between duplicate
measurements from our two staining batches (Figure 4). In
FTLD-Tau, both GM and WM models had Rsq of 0.92; in
FTLD-TDP, the Rsq was 0.75 in GM and 0.78 in WM. All
summary statistics for SB1 and SB2 data are displayed in
Supplementary Table 2.
Step 1: Examine Transformation
Prerequisites in Feasible-Sized Training
Sets
Since it is not practical to use a large number of duplicate tissue
samples for each prospective staining batch in all future large-
scale studies, we aimed to first determine whether a small set
of tissue stained in duplicate could suffice to obtain an accurate
transformation. We used samples of N = 12 and N = 24 as our
training sets, i.e., half- or one-full rack in our staining batches.
We performed iterations (100×) of linear modeling in training
sets, looking at Rsq values as transformation prerequisites, and
beta and intercept as equivalence factors (Table 2). In FTLD-Tau
GM, the mean Rsq was 0.92± 0.03 in N = 24 sets and 0.91± 0.05
in N = 12 sets; the models were significant (p < 0.05) in 100%
of N = 24 iterations and N = 12 iterations. In FTLD-Tau WM,
the mean Rsq was 0.91 ± 0.02 in N = 24 sets and 0.90 ± 0.06
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FIGURE 3 | Bland-Altman plots of test-retest agreement between duplicate measurements of pathology from two distinct staining batches. Bland-Altman plots
show test-retest agreement between SB1 and SB2 measurements of digital pathology (i.e., ln %AO). The green dashed line indicates the mean difference between
SB1 and SB2 measurements, while the red solid lines mark the 95% limits of agreement between the two measurements. We find that mean difference between
SB1 and SB2 significantly differs from zero (p < 0.001) in FTLD-Tau (A) and FTLD-TDP (B) in both GM and WM. FTLD-Tau, frontotemporal lobar degeneration with
inclusions of the tau protein; FTLD-TDP, frontotemporal lobar degeneration with inclusions of the transactive response DNA-binding protein 43 kDa; GM, gray matter;
SB1, staining batch 1 (original); SB2, staining batch 2 (new); WM, white matter.
in N = 12 sets; the models were significant (p < 0.05) in 100%
of N = 24 iterations and N = 12 iterations. In FTLD-TDP GM,
the mean Rsq was 0.76 ± 0.10 in N = 24 sets and 0.72 ± 0.18
in N = 12 sets; the models were significant (p < 0.05) in 100%
of N = 24 iterations and 97% of N = 12 iterations. In TDP WM,
the mean Rsq was 0.78 ± 0.07 in N = 24 sets and 0.76 ± 0.12
in N = 12 sets; the models were significant (p < 0.05) in 100%
of N = 24 iterations and 100% of N = 12 iterations. Overall
we found a consistent strong linear association between %AO
measurements from different staining batches equally in N = 24
and N = 12 training sets in FTLD-Tau, while FTLD-TDP had
greatest reliability of this association in training sets of N = 24
sample size (Table 2).
Step 2: Cross-Validate Transformation
Outcomes in Independent Testing Sets
Next, we cross-validated equivalence factors derived in Step
1 on independent testing sets including all remaining tissue
samples not used in the training set (Table 3). We were
interested in comparing transformation outcomes resulting from
the application of equivalence factors from N = 12 as opposed
to N = 24 training sets. We looked at the ICC as main
transformation outcome and we set a value of ≥0.8 as our
threshold for an optimal transformation. In FTLD-Tau GM,
N = 24 training sets resulted in a mean ICC of 0.95 ± 0.02
in testing sets, while N = 12 training sets resulted in a mean
ICC of 0.95 ± 0.01. Similarly, in FTLD-Tau WM, N = 24
training sets resulted in a mean ICC of 0.95 ± 0.02 in
testing sets, while N = 12 training sets resulted in a mean
ICC of 0.95 ± 0.01. We obtained optimal transformation
outcomes in 100% of transformations in both GM and WM
in FTLD-Tau (Table 3). In FTLD-TDP GM, N = 24 training
sets resulted in a mean ICC of 0.82 ± 0.05 in testing sets,
while N = 12 training sets resulted in a mean ICC of
0.81 ± 0.06. We found optimal transformation outcomes in 72%
of transformations using N = 24 training sets and 70% using
N = 12 training sets, while most remaining transformations
(i.e., 25% using N = 24 training sets and 26% using N = 12
training sets) resulted in a moderate ICC between 0.7 and
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FIGURE 4 | Linear relationship between duplicate measurements of pathology from two distinct staining batches (SB1 Y-axis, SB2 X-axis). Scatterplots display the
linear relationship between duplicate measurements of digital pathology (i.e., ln %AO) from SB1 (y-axis) and SB2 (x-axis) in FTLD-Tau (A) and FTLD-TDP (B), for both
GM and WM measurements. In FTLD-Tau GM, the model Rsq is 0.92 (p < 0.001); in FTLD-Tau WM, the model Rsq is 0.92 (p < 0.001). In FTLD-TDP GM, the
model Rsq is 0.75 (p < 0.001); in FTLD-TDP WM, the model Rsq is 0.78 (p < 0.001). FTLD-Tau, frontotemporal lobar degeneration with inclusions of the tau protein;
FTLD-TDP, frontotemporal lobar degeneration with inclusions of the transactive response DNA-binding protein 43 kDa; GM, gray matter; ln %AO, natural logarithmic
transformation of percent area occupied by pathology; Rsq, R squared; SB1, staining batch 1 (original); SB2, staining batch 2 (new); WM, white matter.
0.8. In FTLD-WM, N = 24 training sets resulted in a mean
ICC of 0.86 ± 0.03 in testing sets, while N = 12 training
sets resulted in a mean ICC of 0.85 ± 0.03. We obtained
optimal transformation outcomes in 98% of transformations
using N = 24 training sets and 95% using N = 12 training
sets (Table 3). Based on these frequencies, in prospective
analyses we propose to use at least N = 12 training sets for
FTLD-Tau and N = 24 training sets for FTLD-TDP, where
we find the best compromise between feasibility of use and
reliability of outcomes.
Step 3: Determine Functional
Improvement After Transformation
Finally, we applied our cross-validated method to a single,
randomly obtained train-test split to determine the improvement
in functional outcomes, such as the reduction in batch-related
difference between digital measurements. We checked the
reliability of our transformation method as in the prior
steps, by looking at transformation prerequisites in training
sets (FTLD-Tau = 12, FTLD-TDP = 24) and transformation
outcomes in testing sets (FTLD-Tau = 27, FTLD-TDP = 29)
(Table 4). In FTLD-Tau, training sets had an Rsq of 0.92 in
GM and 0.97 in WM. In complementary testing sets, ICC
was 0.96 in GM and 0.95 in WM. Before transformation,
Bland-Altman statistics showed highly significant mean
difference between duplicate %AO measurements in both
GM and WM. After transformation, we found a significant
reduction in absolute difference (i.e., delta abs-diff) in
both GM (p < 0.001) and WM (p < 0.001) %AO to a
mean difference that approached zero, suggesting improved
test-retest agreement (Figure 5). In FTLD-TDP, training
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TABLE 2 | Transformation prerequisites and equivalence factors from iterated (×100) linear regression in feasible-sized training sets (Step 1).
Size (N) Iterations Rsq mean Rsq SD Rsq 2.5Q–97.5Q Beta mean Beta SD Beta 2.5Q–97.5Q Itc mean Itc SD Itc 2.5Q–97.5Q
FTLD-Tau GM Tot 1 0.92 – – – 0.89 – – – 1.08 – – –
24 100 0.92 0.03 0.87 0.96 0.89 0.04 0.80 0.96 1.08 0.04 0.99 1.16
12 100 0.91 0.05 0.79 0.98 0.89 0.07 0.74 1.01 1.09 0.11 0.88 1.31
FTLD-Tau WM Tot 1 0.92 – – – 0.90 – – – 1.11 – – –
24 100 0.91 0.02 0.88 0.94 0.90 0.03 0.84 0.96 1.12 0.09 0.93 1.25
12 100 0.90 0.06 0.77 0.97 0.90 0.08 0.75 1.05 1.12 0.19 0.79 1.49
FTLD-TDP GM Tot 1 0.75 – – – 1.00 – – – 0.96 – – –
24 100 0.76 0.10 0.44 0.87 1.00 0.14 0.74 1.25 0.95 0.35 0.37 1.67
12 100 0.72 0.18 0.26 0.94 0.98 0.22 0.57 1.41 0.90 0.55 −0.12 1.98
FTLD-TDP WM Tot 1 0.78 – – v 0.81 – – – 0.09 – – –
24 100 0.78 0.07 0.64 0.87 0.81 0.07 0.65 0.93 0.10 0.29 −0.56 0.57
12 100 0.76 0.12 0.47 0.92 0.81 0.13 0.61 1.10 0.14 0.53 −0.66 1.33
FTLD-Tau, frontotemporal lobar degeneration with inclusions of the tau protein; FTLD-TDP, frontotemporal lobar degeneration with inclusions of the transactive response
DNA-binding protein 43 kDa; GM, gray matter; Itc, intercept; N, number of tissue samples; Q, quantile; Rsq, R squared; SD, standard deviation; Tot, total dataset; WM,
white matter. Table shows transformation prerequisites (i.e., Rsq) and equivalence factors (i.e., beta, intercept) in randomly subsampled training sets of small sample
size, corresponding to a half (N = 12) or one full rack (N = 24) in staining batches, feasible for use in prospective transformations. We performed 100 iterations of the
linear regression, and we report mean, standard deviation and a non-parametric quantile-based confidence interval (2.5–97.5% of the distribution) for R squared, beta
and intercept values of the linear models. For comparison, we also show these parameters from linear models obtained in the total datasets (i.e., FTLD-Tau GM/WM,
FTLD-TDP GM/WM).
TABLE 3 | Transformation outcomes in independent complementary testing sets (Step 2).
Training sets (Step 1) Independent testing sets (Step 2)
Size (N) Iterations Size (N) ICC mean ICC SD ICC 2.5Q–97.5Q ICC ≥ 0.8 (%)
FTLD-Tau GM 24 100 15 0.95 0.02 0.90 0.98 100
12 100 27 0.95 0.01 0.92 0.97 100
FTLD-Tau WM 24 100 15 0.95 0.02 0.91 0.98 100
12 100 27 0.95 0.01 0.92 0.96 100
FTLD-TDP GM 24 100 29 0.82 0.05 0.69 0.91 72
12 100 41 0.81 0.06 0.69 0.89 70
FTLD-TDP WM 24 100 29 0.86 0.03 0.80 0.91 98
12 100 41 0.85 0.03 0.78 0.89 95
FTLD-Tau, frontotemporal lobar degeneration with inclusions of the tau protein; FTLD-TDP, frontotemporal lobar degeneration with inclusions of the transactive response
DNA-binding protein 43 kDa; ICC, intraclass correlation coefficient; GM, gray matter; N, number of tissue samples; Q, quantile; SD, standard deviation; WM, white matter.
We performed 100 iterations of linear regression in training sets of N = 12 and N = 24 sample size, and applied equivalence factors to independent testing sets including all
remaining tissue samples in each iteration. Here, we report transformation outcomes (i.e., ICC) in these complementary testing sets. We report mean, standard deviation
and a non-parametric quantile-based confidence interval (2.5–97.5% of the distribution) for the ICC. Additionally, we report the frequency of optimal transformations out
of 100 iterations per group based on our threshold of ICC ≥ 0.8.
sets had an Rsq of 0.70 in GM and of 0.75 in WM. In
complementary testing sets, ICC was 0.88 in both GM and
WM. While before transformation, the mean difference
between duplicate %AO measurements was highly significant
using Bland-Altman statistics, after transformation there
was a significant reduction in absolute difference (i.e., delta
abs-diff) in both GM (p < 0.001) and WM (p < 0.001)
%AO to a mean difference that approached zero, similarly
suggesting improved test-retest agreement (Figure 6). These
findings help us validate the functional implications of our
SOP, where we propose to use a small sample of tissue
stained in each prospective staining batch to transform
newly acquired data into values equivalent to previously
generated data, thereby accounting for staining batch
effects (Figure 7).
Finally, we performed a proof-of-concept power analysis to
determine the magnitude of improved statistical power after
the application of our transformation method, compared to
a standard approach using datasets of untransformed %AO
obtained from two distinct staining batches. We compared
the use of merged untransformed (SB1 + SB2) and merge
transformed (SB1 + t-SB2) data in tissue from ANG (FTLD-
Tau = 20, FTLD-TDP = 38), and we estimated the necessary
sample size to detect a small, medium or large effect
size when compared to another hypothetical brain region
(power = 0.8, alpha = 0.05). We found that the application of
our transformation method resulted in a reduction in estimated
sample size required for analysis, i.e., −40% in FTLD-Tau GM,
−34% in FTLD-Tau WM, −20% in FTLD-TDP GM, and −30%
in FTLD-TDP WM (Table 5).
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TABLE 4 | Application of transformation method in a single train-test split to determine reduction in batch-related difference in measurements (Step 3).
Train (N) Rsq Beta Itc Test (N) ICC Mean diff before BA before sig. Mean diff after BA after sig. Delta abs- diff Delta abs-diff sig.
1× train-test split FTLD-Tau
GM 12 0.92 0.91 1.05 27 0.96 −1.16 5.04e-13 −0.05 0.513 −0.86 2.89e-11
WM 12 0.97 0.86 1.03 27 0.95 −1.32 2.08e-11 −0.03 0.808 −0.79 4.92e-07
1× train-test split FTLD-TDP
GM 24 0.70 1.01 0.89 29 0.88 −1.02 1.48e-08 −0.16 0.226 −0.61 1.92e-08
WM 24 0.75 0.79 −0.08 29 0.88 −1.02 4.37e-08 −0.20 0.117 −0.50 1.31e-04
BA, Bland-Altman statistics; Delta abs-diff, change in absolute difference; diff, difference; FTLD-Tau, frontotemporal lobar degeneration with inclusions of the tau protein;
FTLD-TDP, frontotemporal lobar degeneration with inclusions of the transactive response DNA-binding protein 43 kDa; ICC, intraclass correlation coefficient; Itc, intercept;
GM, gray matter; N, number of tissue samples; Rsq, R squared; sig., significance; WM, white matter. Here, we display the results of the application of our cross-validated
transformation method in a single randomly obtained train-test split. On the left side, table shows transformation prerequisites (i.e., Rsq) and equivalence factors (i.e., beta,
intercept) in training sets (GM/WM in FTLD-Tau and FTLD-TDP). On the right side, we report corresponding transformation outcomes (i.e., ICC) in the complementary
testing sets. Additionally, we look at measures of test-retest agreement, i.e., mean difference between SB1 and SB2 before and after the transformation, with Bland-
Altman statistics (p < 0.05, significant mean difference between SB1 and SB2/t-SB2; p > 0.05, non-significant mean difference between SB1 and SB2/t-SB2), as well
as the decrease in absolute difference tested with a one-sample t-test statistics (p < 0.05, significant reduction in difference between duplicate measurements after the
transformation).
Exploratory Analysis: Application of
Validated Method to Other Sources of
Pre-analytical Variability
We tested whether this method could help account for other
sources of pre-analytical variability. In our brain bank, tissue
that is not sampled for IHC analysis is frozen at −80 degrees
for use in biochemical studies (Toledo et al., 2014). It would
be advantageous to harvest frozen tissue in key regions that
are not routinely sampled by traditional protocols (Montine
et al., 2012) for more extensive regional and bilateral analyses
in FTD (Irwin et al., 2018; Giannini et al., 2019). To test this
approach, we compared digital %AO measurements between
standard fresh tissue fixed at autopsy and legacy frozen tissue
samples. We obtained tissue samples from frozen cortical slabs
adjacent to those sampled fresh at autopsy (N = 16 in FTLD-
Tau, N = 12 in FTLD-TDP), and allowed the frozen samples to
thaw prior to fixation overnight in 10% neutral buffered formalin.
All subsequent processing was done in an identical manner to
standard samples obtained fresh at autopsy (Toledo et al., 2014).
Frozen-fixed and standard (i.e., fresh-fixed) tissue samples from
adjacent cortical slabs in the MFC were stained in the same
staining batch, and %AO was measured using our standard
digital image approach (please see methods). We performed
equivalence analyses and found a significant linear association
between frozen-fixed and fresh-fixed duplicate measurements
in both FTLD-Tau (Rsq = 0.77, p < 0.001) and FTLD-TDP
(Rsq = 0.70, p < 0.001) in the MFC region (Supplementary
Figure 2), suggesting that it may be possible to use a similar
SOP approach to the one we propose for staining batch effects
(Figure 7) to account for other pre-analytical factors, such as
processing of frozen tissue for IHC analysis.
Analysis of Generalizability: Replication
of Validation Outcomes Using an
Open-Source Digital Platform
We examined whether our findings of staining batch variability
and improved agreement after transformation were reproducible
using another digital histopathology platform, i.e., QuPath
(Bankhead et al., 2017), by importing our color deconvolution
algorithm parameters (Supplementary Table 1) in this software
and performing identical analyses. First, we found that %AO
measurements obtained from identical images in Halo and
QuPath platforms were highly correlated for both FTLD-Tau
and FTLD-TDP (Rsq ≥ 0.84, p < 0.001; Supplementary
Figure 3), suggesting a strong association of %AO measurements
of pathology across platforms. Next, we compared duplicate
measurements between staining batches in the total FTLD-
Tau and FTLD-TDP datasets (Supplementary Table 3), and
found a significant difference between SB1 and SB2 QuPath
measurements (p < 0.001 all), which were linearly related
(p < 0.001 all) similar to our analyses above (Figures 3, 4
and Table 2). Application of the transformation method to
QuPath data enabled to account for this variability as in Step
3 (Supplementary Table 4); Bland-Altman analysis showed
improved test-retest agreement after transformation in both
FTLD-Tau and FTLD-TDP (Supplementary Figures 4, 5)
similar to our analyses using the Halo platform (Table 4 and
Figures 5, 6).
Finally, we performed an exploratory analysis to test the ability
of an empiric stain detection algorithm approach to account
for staining batch effects of both haematoxylin and DAB in
SB2. We used the “Estimate stain vectors” function in QuPath
to define optimum RGB values for DAB and haematoxylin
in SB2, resulting in optimized detection algorithms for SB2
(Supplementary Table 5). We thus compared the optimized
SB2 measurements to original SB1 measurements in QuPath
in the total dataset (see section “Materials and Methods”).
Using this approach, we found good test-retest agreement
between %AO values obtained using the original algorithm
in SB1 and duplicate measurements in SB2 analyzed with
the optimized algorithm (Supplementary Figure 6), similar
to our results using the transformation approach in QuPath
(Supplementary Table 4 and Supplementary Figures 4, 5) and
in Halo (Table 4 and Figures 5, 6). These findings suggest that
digitally accounting for both haematoxylin and DAB provides
for a comparable effect as our validated statistical transformation
method (Figure 7).
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FIGURE 5 | Bland-Altman plots of test-retest agreement between duplicate measurements of pathology before vs. after transformation in FTLD-Tau. Plots portray
test-retest agreement between duplicate measurements of digital pathology (i.e., ln %AO) in FTLD-Tau from SB1 and SB2 before and after transforming the data
using our validated linear regression-based method. Here we illustrate the reduction in batch-related difference in digital measurements resulting from the application
of our transformation method in a single train-test split in FTLD-Tau (Step 3). The green dashed line indicates the mean difference between SB1 and SB2
measurements, while the red solid lines mark the 95% limits of agreement between the two measurements. We find that mean difference between SB1 and
SB2/t-SB2 is significantly different from zero before transformation (p < 0.05, one-sample t-test), whereas it is not significantly different from zero after transformation
(p > 0.05) in both GM and WM. FTLD-Tau, frontotemporal lobar degeneration with inclusions of the tau protein; GM, gray matter; SB1, staining batch 1 (original);
SB2, staining batch 2 (new); t-SB2, transformed staining batch 2 (new); WM, white matter.
DISCUSSION
Here we provide a statistically rigorous evaluation of pre-
analytical variability in IHC staining intensity in FTLD
(Figure 1), we develop an SOP for transformation of digital
pathology measurements to account for this variability in both
GM and WM (Figure 7), and we generalize our findings using
a second, open-source, image analysis platform. First, Bland-
Altman statistics suggests that variation in staining intensity is
influential for measurements of digital pathology in both FTLD-
Tau and FTLD-TDP in GM and WM (Figure 3), necessitating a
method to transform values from different staining batches into
equivalent values for more accurate analysis. Based on a highly
correlated linear relationship between duplicate measurements
of pathology from two different staining batches (Figure 4) in
FTLD-Tau (GM: Rsq = 0.92, WM: Rsq = 0.92) and FTLD-TDP
(GM: Rsq = 0.75, WM: Rsq = 0.78), we validate the use of
a regression-based transformation method using a small set of
tissue stained in duplicate to merge data obtained from different
staining batches. First, we find that smaller datasets (N = 12–24)
have adequate transformation prerequisites (i.e., Rsq), providing
a consistently strong linear relationship (Table 2) to serve as
training sets for our transformation protocol. Second, we find
that training sets of N = 12 sample size in FTLD-Tau and N = 24
in FTLD-TDP result in optimal or near optimal transformation
outcomes in complementary testing sets (Table 3). After applying
our final transformation method, we observe a significant
reduction in the difference between duplicate measurements
from different staining batches in both FTLD-Tau (p < 0.001)
and FTLD-TDP (p < 0.001) (Figures 5, 6). Finally, we
perform a proof-of-concept power analysis, which shows that
the application of our transformation method improves statistical
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FIGURE 6 | Bland-Altman plots of test-retest agreement between duplicate measurements of pathology before vs. after transformation in FTLD-TDP. Plots portray
test-retest agreement between duplicate measurements of digital pathology (i.e., ln %AO) in FTLD-TDP from SB1 and SB2 before and after transforming the data
using our validated linear regression-based method. Here we illustrate the reduction in batch-related difference in digital measurements resulting from the application
of our transformation method in a single train-test split in FTLD-TDP (Step 3). The green dashed line indicates the mean difference between SB1 and SB2
measurements, while the red solid lines mark the 95% limits of agreement between the two measurements. We find that mean difference between SB1 and
SB2/t-SB2 is significantly different from zero before transformation (p < 0.05, one-sample t-test), whereas it is not significantly different from zero after transformation
(p > 0.05) in both GM and WM. FTLD-TDP, frontotemporal lobar degeneration with inclusions of the transactive response DNA-binding protein 43; GM, gray matter;
SB1, staining batch 1 (original); SB2, staining batch 2 (new); t-SB2, transformed staining batch 2 (new); WM, white matter.
power for analysis in both FTLD-Tau and FTLD-TDP, decreasing
the required sample size by 20–40% (Table 5). Altogether, these
results suggest that it is possible and advantageous to account
for pre-analytical variability statistically, and this process can
be performed using open-source platforms for greater rigor,
reproducibility of digital measurements, and sharing of research
methodologies. Therefore, these data have strong implications for
digital pathology studies in neurodegenerative disease.
Digital measurements of pathology provide a novel and
high-throughput means to obtain objective data of regional
disease severity in the central nervous system of FTLD
and related disorders. This approach allows for complex
statistical modeling of quantitative pathology data for more
fine-grained clinicopathological studies (Neltner et al., 2012;
Hamilton et al., 2014; Walker et al., 2015; Coughlin et al.,
2018; Ferman et al., 2018; Giannini et al., 2019). This is of
importance as autopsy tissue remains the gold standard for
diagnosis in neurodegenerative disease, and measurement of
histopathological markers can inform biomarker discovery and
validation. While clinicopathological studies have already been
informative to improve the understanding of pathophysiological
processes and guide clinical diagnostic criteria (Irwin et al.,
2016a, 2017, 2018; Giannini et al., 2017), quantitative digital
pathology has the potential to provide a more objective and
detailed account of neuropathological burden, suitable for
associations with biomarkers, imaging and other measures of
disease (Irwin et al., 2018). Thus, a rigorous approach is needed
to optimize digital pathology measurements for widespread use
in the research community. We previously validated sampling
methods and thresholding algorithms for FTLD (Irwin et al.,
2016b), and successfully applied digital methods to relate
postmortem FTLD histopathology to antemortem cerebrospinal
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TABLE 5 | Outcomes of power analysis using merged SB1 and SB2/t-SB2 data to measure improvement before vs. after the transformation (Step 3).
Merged untransformed Merged transformed Percent
(SB1 + SB2) (SB1 + t-SB2) reduction
ANG SD Effect size Est. sample ANG SD Effect size Est. sample Est. sample (%)
FTLD-Tau GM 1.96 0.8 95 1.52 0.8 58 −39
(N = 20) 1.96 0.5 242 1.52 0.5 146 −40
1.96 0.2 1505 1.52 0.2 906 −40
FTLD-Tau WM 2.17 0.8 116 1.77 0.8 77 −33
(N = 20) 2.17 0.5 296 1.77 0.5 197 −34
2.17 0.2 1845 1.77 0.2 1224 −34
FTLD-TDP GM 1.35 0.8 45 1.20 0.8 36 −20
(N = 38) 1.35 0.5 115 1.20 0.5 92 −20
1.35 0.2 713 1.20 0.2 567 −20
FTLD-TDP WM 1.55 0.8 60 1.30 0.8 42 −29
(N = 38) 1.55 0.5 152 1.30 0.5 107 −30
1.55 0.2 943 1.30 0.2 661 −30
ANG, angular gyrus; Est., estimated; FTLD-Tau, frontotemporal lobar degeneration with inclusions of the tau protein; FTLD-TDP, frontotemporal lobar degeneration with
inclusions of the transactive response DNA-binding protein 43 kDa; GM, gray matter; N, number of tissue samples; SB1, original staining batch; SB2, new staining
batch (untransformed); SD, standard deviation; t-SB2, new staining batch (transformed); WM, white matter. Here, we show a power analysis to estimate the sample size
necessary for an independent samples t-test testing pathology burden (i.e., mean ln %AO) in ANG against any other hypothetical brain region. Our aim was to measure the
improvement in power after transformation by comparing (1) data merged from the original staining batch and the new staining batch without transformation (i.e., merged
untransformed = SB1 + SB2), and (2) data merged from the original staining batch and the new staining batch after transformation (i.e., merged transformed = SB1
+ t-SB2). We calculated ANG SD in these two sets of data and used it as an approximation of the overall variance (ANG vs. hypothetical region). We used effect
sizes of 0.2, 0.5, and 0.8, corresponding to small, medium, and large effect sizes (Cohen, 1988), to estimate the sample size necessary (i.e., Est. sample) to detect a
difference between mean ANG and another hypothetical regional mean. Each power analysis used alpha 0.05 and power 0.8. We measured the change between merged
untransformed and merged transformed data by means of a percent reduction in estimated sample size.
fluid (CSF) (Irwin et al., 2017) and quantitative MRI data (Irwin
et al., 2018; Giannini et al., 2019). We have also used this
approach in Alzheimer’s disease (AD) and Lewy body disease
(LBD) (Coughlin et al., 2018). Here, we validate a statistical
methodology to account for an important pre-analytical factor
in digital histopathology, similar to other approaches previously
used for biofluid (Figurski et al., 2012) or neuroimaging (Cash
et al., 2015) biomarkers, which helps us to account for staining
batch effects in AO% measurements using a set of tissue
stained in duplicate.
A unique aspect to digital pathology is the limited flexibility to
stain large numbers of tissue samples in a single staining batch,
which precludes the inclusion of large amounts of additional
tissue as control sample for our transformation, as opposed
to other biomarkers such as biofluid assays which often use
multiple sets of >96 well plates. Therefore, our approach to
determine a feasible number of tissue samples to use for this
transformation method (i.e., ≤24, which is equivalent to a
standard staining rack) is critical for implementation. We found
relatively consistent goodness of fit (i.e., Rsq) in linear modeling
derived from smaller trainings sets such as N = 12 or N = 24
in FTLD-Tau. FTLD-TDP showed relatively more heterogeneous
transformation prerequisites (i.e., Rsq) in both GM and WM. We
observed that lowering the number of samples in the training set
increases the chance of a weaker linear relationship (Table 2).
There may be several reasons for this observation. FTLD-Tau
pathology has a wider magnitude and variance in overall %AO
based on the morphology of tau inclusions, which in severe
cases cover a large number of pixels (e.g., >70 %AO) (Irwin
et al., 2017), compared to severe sections of FTLD-TDP, which
cover a much smaller range of area (i.e., <5 %AO) (Irwin et al.,
2018). The smaller variance in overall %AO in FTLD-TDP could
potentially lead to an amplification of the effect of small changes
in measurements between batches. Further, due to the small size
of TDP-43 dystrophic neurites in GM and oligodendrocytic TDP-
43 inclusions in WM (Neumann et al., 2009), biological variance
in the amount of FTLD-TDP pathology in a given tissue sample
may be influential even between adjacent sections. There may
also be differences in antibody avidity or sensitivity to antigen
retrieval, which could affect our outcomes focused on staining
batch-related variability (Cummings et al., 2002). We used well-
characterized antibodies (Goedert et al., 1995) with optimized
staining parameters used in our lab and identical processing for
both staining batches to reduce the influence of these factors.
It is well known that GM and WM have distinct densities
and morphologies of disease in FTLD pathologies (Irwin et al.,
2015). We therefore chose to analyze these two measures
of disease separately in our validation analyses. In terms
of transformation prerequisites and outcomes, we obtained
relatively similar values between GM and WM within FTLD
pathologies, indicating that these two measures of disease are
affected by staining batch effects to a comparable extent. WM
pathology in FTLD is important and understudied, especially
using digital pathology methods. Indeed, in our most recent
work we found greater overall burden of WM pathology in
FTLD-Tau compared to FTLD-TDP (Irwin et al., 2018), which
could help differentiate these pathologies during life (McMillan
et al., 2013). While we now use a standardized sampling
procedure (Irwin et al., 2017, 2018) of adjacent WM from
cortical sections, future work will aim to explore sampling of
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FIGURE 7 | Standard operating procedure for prospective use of our
validated transformation method. Panel outlines a standard operating
procedure (SOP) for prospective addition of new data to existing datasets
where we use our validated transformation method to account for staining
batch effects. FTLD-Tau, frontotemporal lobar degeneration with inclusions of
the tau protein; FTLD-TDP, frontotemporal lobar degeneration with inclusions
of the transactive response DNA-binding protein 43; LMN, number of tissue
samples; SB1, staining batch 1 (original); SB2, staining batch 2 (new); SOP,
standard operating procedure; t-SB2, transformed staining batch 2 (new).
specific deep WM tracks at the time of autopsy. Optimizing
and validating pre-analytical methods for WM pathology analysis
will be crucial to further the understanding of subcortical
patterns of disease.
It is notable that the optimal size of training sets for an
accurate transformation differed between FTLD-Tau and
FTLD-TDP. These data suggest that transformation SOPs
should be empirically determined for each disease (e.g.,
AD, LBD), and potentially for each antibody used in digital
pathology studies. Here, we find optimal training-set sizes
(i.e., ≥24) that are practical to use in prospective studies
(i.e., requiring only half or one additional staining rack).
It may be possible to further improve this transformation
method using a larger number of training data by means
of a tissue microarray slide with >100 pathology cores
(Walker et al., 2017) in prospective staining runs, or tissue
slides with standardized synthetic protein of interest for
transformation (Sompuram et al., 2015). Our study provides
important proof-of-concept findings for the use of linear
regression to account for staining batch effects, thereby
improving accuracy of digital histopathology, and new
available tools may be used to facilitate and advance the
implementation of this method.
Indeed, our method enabled us to correct for a large amount
of variability due to staining batch effects (Figures 4, 5).
We were additionally interested in the implications of our
method to improve clinicopathological correlations. Using a
power analysis to compare the effects of our transformation
on merged data from distinct staining batches, we found a
positive improvement in both FTLD-Tau and FTLD-TDP after
transformation (Table 5). This is of great importance for FTLD,
which is a relatively rare neurodegenerative disease (Knopman
and Roberts, 2011), and may also be beneficial in other more
common disorders to preserve valuable autopsy tissue and
improve statistical power.
Our study proposes and validates a method to account
for staining batch effects in digital histopathology, but has
some limitations. Relying on a statistical estimation, our
proposed method does not help to escape other individual-
sample sources of variability in digital measurements, such
as artifacts or damaged tissue. For this reason we performed
rigorous inspection of all tissue sections used in this study
and we carefully excluded those that were not of sufficient
quality for usage and comparison across staining batches.
Therefore, in the selection of tissue samples to use in prospective
transformations, it is crucial to ensure that anomalous sections
with observable defects are not included. While (semi-)adjacent
tissue sections compared across staining batches seemed near-
identical by visual inspection, biological variation in pathology
distribution as well as ROI sampling between (semi-)adjacent
tissue sections may partly confound the linear relationship
between different staining batches measured in this study.
However, the highly consistent linear relationship between the
two staining batches (Figure 4) suggests that these effects may be
minimal. Additionally, there may be other pre-analytical factors
that influence digital pathology measurements that have not been
accounted for by our designed methodology. While the intensity
of haematoxylin counterstain may be variable and introduce
further noise in the digital measurements, the Halo quantification
accounted for the counterstain in color deconvolution algorithms
(Supplementary Table 1). Moreover, in our supplementary
analysis using QuPath, we empirically derived an optimized RGB
color deconvolution algorithm for both haematoxylin and DAB
in SB2 (Supplementary Table 5) with similar favorable results
for test-retest agreement (Supplementary Figure 6) as in our
transformation approach (Figure 7). We used a transmitted light
microscopy scanning system with identical image acquisition
features and resolution. Further work is needed to validate image
acquisition across different scanners at different labs as another
pre-analytic factor that may be optimized to increase the rigor
and reproducibility of digital histopathology for multicenter
studies in neurodegenerative disease (Rojo et al., 2003). Further,
the use of other available methods of digital histopathology
such as multispectral analysis may improve quantification (Van
Der Loos, 2008). In an exploratory analysis, we suggested a
potential application of our methodology to equate data with
alternative fixation methods (i.e., fresh-fixed vs. frozen-fixed
tissue), based on an observed consistent linear relationship
between duplicate measurements from these two approaches
(Supplementary Figure 2). These findings suggest that the use
of our SOP may be extended to other identifiable sources of
pre-analytical variability, granted that the divergence between
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digital measurements of pathology can be approximated to a
linear relationship. Moreover, future targeted studies will be
necessary to understand and address all potential sources of pre-
analytical variability in digital histopathology systematically, and
examine these variables carefully in large tissue samples with
targeted study designs.
To conclude, we find that staining batch affects can
significantly alter the accuracy of digital pathology measurements
in neurodegenerative disease research. To account for this
problem, we propose and validate a novel statistical approach
using linear regression that enables to transform measurements
from distinct staining batches into equivalent values, and to
merge these data in a unique dataset without significant batch-
related variability. Given the generalizability of our findings
in an open-source digital pathology platform, we suggest that
our method may provide a valid solution to researchers using
different image analysis platforms. This approach will allow for
more accurate and intercomparable measurements of digital
pathology, and it will facilitate the creation of large-scale
“libraries” of digital pathology data for future translational work.
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